Fas ligand (FasL) is a member of the tumor necrosis family and when bound to its receptor, Fas, induces apoptosis. It plays important roles in immune response, degenerative and lymphoproliferative diseases, development and tumorigenesis. It is also involved in generation of immune privilege sites in the eye and testis. Harnessing the power of this molecule is expected to lead to a powerful chemotherapeutic. We describe the construction and characterization of replication-deficient adenoviral vectors that express a fusion of murine FasL and green fluorescent protein (GFP). FasL-GFP retains full activity of wild-type FasL, at the same time allowing for easy visualization and quantification in both living and fixed cells. The fusion protein is under the control of a tetracycline-regulated gene expression system. Tight control of expression is achieved by creating a novel 'double
Introduction
FasL is a 40-kDa type II membrane protein belonging to the tumor necrosis factor family. 1 Its receptor Fas (APO-1, CD95) is a 45 kDa type I membrane protein and belongs to the TNF/nerve growth factor receptor superfamily. 2, 3 Binding of FasL (and certain anti-Fas antibodies) to Fas causes receptor oligomerization and sends a signal through a complex caspase pathway, resulting in rapid death of receptor-bearing cells through apoptosis. [4] [5] [6] [7] Most cell types examined express Fas at some level and are probably susceptible to Fas-mediated apoptosis. 8 Expression of FasL is primarily restricted to cells of the immune system (T, B and NK cells). High levels of expression of FasL on activated cytotoxic T and NK lymphocytes cause apoptosis in the receptor-bearing target cells -one of the two major cytotoxic mechanisms employed by killer T cells. 9, 10 Since both ligand and receptor are membrane proteins, Fas-induced apoptosis is normally mediated through cell-cell contact. However, a soluble form of FasL is also produced by some cells recombinant' Ad vector, in which the tet-responsive element and the transactivator element are built into the opposite ends of the same vector to avoid enhancer interference. Expression can be conveniently regulated by tetracycline or its derivatives in a dose-dependent manner. The vector was able to deliver FasL-GFP gene to cells in vitro efficiently, and the expression level and function of the fusion protein was modulated by the concentration of doxycycline. This regulation allows us to produce high titers of the vector by inhibiting FasL expression in an apoptosis-resistant cell line. Induction of apoptosis was demonstrated in all cell lines tested. These results indicate that our vector is a potentially valuable tool for FasL-based gene therapy of cancer and for the study of FasL/Fas-mediated apoptosis and immune privilege. Gene Therapy (2000) 7, 875-885.
and has been shown to have a somewhat altered activity, depending on the target cell. 11, 12 Discovery of the expression of FasL in the immunoprivileged sites such as the eye and testis led to a model which proposed that the infiltrating inflammatory cells were rapidly killed through the FasL-Fas pathway when they came in contact with the privileged cells expressing the ligand. [13] [14] [15] This model was further supported by observations that tumor cells of some cancers also express FasL, which they apparently use to kill Fas-bearing intratumoral T cells efficiently and thus evade the immune response. [16] [17] [18] In some cases tumors develop resistance to FasL-mediated apoptosis by acquiring mutations that either block the transduction of the apoptotic signal through the pathway, or make the cells insensitive to it. [19] [20] [21] Recently, a number of attempts have been made to deliver and express exogenous FasL in order to reduce the host immune responses to vector-transduced cells. [22] [23] [24] [25] [26] At the same time, a similar strategy was proposed to attack solid tumors and force their cells to undergo apoptosis. 27, 28 Interestingly, in both cases, similar vectors were used, namely replication-defective adenoviral constructs with the FasL expression driven by a strong promoter such as the human cytomegalovirus immediateearly promoter/enhancer (CMVie). Reports on progress in both fields have been contradictory, emphasizing the complexity of the FasL role in the organism. Clearly, it would be of benefit to determine the responses of various cell types to different levels of FasL expression both in vitro and in vivo. With that in mind, we set out to develop a FasL expression system with the following features: the ability to deliver FasL to a wide range of cell types both in vitro and in vivo, inducible and regulatable expression of exogenous FasL, and a method to quantify easily and reliably the levels and cellular localization of the exogenous FasL. Here, we report construction of a fusion protein, which contains the full sequence of green fluorescent protein (GFP) linked to a 10 amino acid N-terminal truncation of murine FasL ORF. This protein, FasL-GFP, was placed under the control of an inducible tetracyclineresponsive element (TRE) promoter 29 and both FasL-GFP and tetracycline-responsive transactivator (tTA) expression cassettes were incorporated into an Ad5-derived replication-deficient vector. We now demonstrate that this vector, Ad/FasL-GFP TET , is able to deliver FasL-GFP to transformed and primary cell lines, with the expression of the fusion protein in those cells regulated by varying the level of doxycycline. Amounts of FasL-GFP can be easily detected and quantified through the fluorescence of its GFP component, and correlated with the levels of apoptosis in the target and neighboring cells.
Results

Functional analysis of FasL and FasL-GFP proteins
In order to demonstrate that the Fas ligand-GFP (FasL-GFP) fusion protein retains full FasL activity, we have analyzed and compared the function of the FasL and FasL-GFP proteins by using transient DNA transfections into cells susceptible to Fas-mediated apoptosis. Triplicates of wells of HeLa cells were transfected with vectors expressing FasL, FasL-GFP or ␤-galactosidase as a control. At 24 h after transfection, cells were fixed and analyzed for apoptosis by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) kit. The results are shown in Figure 1 . Typically, transfection efficiencies between 10 and 25% were achieved as determined by X-gal staining of cells transfected with pcDNA3-LacZ ( Figure 1D ). Large numbers of HeLa cells transfected with vectors expressing either FasL or FasL-GFP showed typical apoptotic morphology (such as membrane blebbing and loss of adherence) and stained positive (dark brown) in the TUNEL assay ( Figure 1A and B) . No cells transfected with a control plasmid underwent apoptosis ( Figure 1C ). The numbers of apoptotic cells in wells transfected with FasL-GFP vector were reproducibly similar to those transfected with FasL vector, suggesting that the wild-type and fusion proteins have comparable activity.
Construction and characterization of adenoviral vectors
Our goal was to produce large amounts of adenoviral vectors in which the FasL expression could be regulated. This regulation will allow us to control the levels of FasL expression in target cells to facilitate the study of its biological effects and to control potential adverse effects when the vector is administered to animals as a therapy. In addition, amplification of rAd vectors constitutively expressing FasL or FasL-GFP in 293 cells would be expected to produce low titers 30 because FasL expression causes apoptosis of the virus-producing cells. To achieve the controlled FasL-GFP expression, we designed the rAd/FasL-GFP TET vector in which the FasL-GFP is expressed from a TRE promoter. 29 We inserted CMVie promoter-driven tTA gene (the 'tet-off' element) into the Ad5 E1 region and the TRE-controlled FasL-GFP fusion gene near the right ITR. This strategy was based on the following considerations. First, we wished to deliver the entire tet-regulated expression system using a single vector, rather than using two Ad vectors as have been described previously. 31 We believe that using a single vector allows a more efficient delivery to target cells as well as a more uniform regulation of protein expression. Second, we wished to achieve maximum possible separation between the enhancer elements of the CMVie promoter and the TRE promoter, in order to minimize background (unregulated) expression of FasL-GFP protein ( Figure 2B and C) . By placing the TRE promoter at the right end of the Ad5 genome, a similar result was obtained with respect to the E1A enhancer elements, which are located within the Ad5 packaging signals. 32 These elements have been reported to interact with some promoters cloned into the E1 region. 33 The genomes of recombinant adenoviral vectors used in this study were assembled in vitro in large-scale ligation reactions as schematically shown in Figure 2C . These genomes were then gel-purified and transfected into 293 cells and the resulting cultures were propagated until virus-induced cytopathic effect (CPE) was observed. In the case of vectors expressing ␤-galactosidase or GFP, CPE occurred at significantly earlier time-points than for vectors expressing FasL or FasL-GFP, indicating that adenoviral vector replication was probably deleteriously affected by FasL activity. Primary vector stocks were amplified according to established techniques, and rAd DNA was extracted and examined for structural integrity by restriction enzyme digests.
Amplification of rAd vectors constitutively expressing FasL or FasL-GFP in 293 cells has been reported to produce low titers. 30 Although 293 cells express Ad5 protein E1B 19K, which has Bcl-2-like anti-apoptosis activity, 34 most variants of this cell line (including one available to us) are nevertheless sensitive to apoptosis induction through the Fas pathway.
35 Surprisingly, the same effect was observed with our rAd/FasL-GFP TET vector, even in the presence of high levels of doxycycline. Fluorescence microscopy has revealed that FasL-GFP was produced in 293 cells in the course of vector replication, and that a background expression level was still evident in the presence of doxycycline (data not shown). Therefore, we established a 293 cell line which constitutively expresses CrmA protein. CrmA inhibits the interleukin (IL)-1beta converting enzymes (ICE; caspases) and is therefore a potent and specific inhibitor of Fas and TNF␣-mediated apoptosis. 36 As expected, the titers of rAd/FasL and rAd/FasL-GFP TET in 293 cells were typically 30-to 100-fold lower than titers of rAd/LacZ or rAd/GFP. Comparison of titers of rAd vectors with FasL activity demonstrated a substantial improvement (between eight-and 12-fold) in the yield of these vectors when they were produced in 293CrmA cells ( Figure 3) . Amplification of the control vector rAd/LacZ in either 293 or 293CrmA cells resulted in essentially the same yield ( Figure 3 ). Subsequently, generation and amplification of all vectors with FasL activity was carried out in 293CrmA cells.
Figure 1 Both FasL and FasL-GFP fusion protein induce apoptosis in target cells. Thirty-five mm dishes were seeded with 10 5 HeLa cells. After 24 h, cells were transfected with 0.8 g each of (A) pC.Fsl, (B) pC.GFsl or (C, D) pcDNA3.LacZ. Twenty-four h after transfection, cells were either stained for apoptosis using the TUNEL kit (A, B, C) or for ␤-galactosidase expression using X-gal stain (D). Transfection efficiency was estimated to be between 10 and 25% based on (D).
Induction of apoptosis by adenovirus-mediated FasL expression Adenoviral vector-mediated delivery of a gene with FasL activity to a target cell that expresses Fas receptor should result in a Fas-mediated apoptosis of the target cell, as well as of those cells that are in direct contact with the target cell (bystander effect). To demonstrate adenovirusmediated FasL expression functionally, we transduced HeLa cells with rAd/FasL-GFP TET at different multiplicities of infection (MOI). At 24 h after transduction, cells were analyzed for apoptosis. As shown in Figure  4A Detection and cellular localization of FasL-GFP fusion protein Wild-type FasL is a type II membrane protein. To demonstrate that the FasL-GFP fusion protein is also targeted to cellular membrane, we took advantage of the fluorescence of its GFP component, which can be detected in 
.GFsL vector. This plasmid contains Ad5 (sub360) sequences from the unique EcoR1 site (27333 bp) to the right ITR (35935 bp), with E3 and E4 deletions (the Orf6 of E4 is retained). The diagram shows the structure of the regulatable FasL-GFP expression cassette, consisting of the TRE promoter, FasL-GFP fusion protein and bovine growth hormone (BGH) poly A. This cassette was inserted into a MCS at 35810 bp. (C) In vitro assembly of the rAd/FasL-GFP TET vector. The region of the junction between the GFP and FasL reading frames is expanded.
Other rAd vectors were generated using a similar strategy.
living cells using a fluorescent microscope with a FITC filter set. We have used this technique to observe the expression and cellular localization of our FasL-GFP fusion protein when expressed from rAd vector. In HeLa cells, expression of FasL-GFP causes apoptosis at protein levels close to the detection threshold of GFP (data not shown). Therefore, the expression of FasL-GFP was analyzed in primary rat myoblasts, which we found to be relatively resistant to FasL-induced apoptosis. High levels of FasL-GFP expression can be detected in myoblasts at 24 h after infection with rAd/FasL-GFP TET at an MOI of 10. Membrane-associated expression of FasL-GFP is evident in the majority of the transduced cells ( Figure  5A ). In contrast, the fluorescence pattern of GFP itself indicates even distribution in the cells ( Figure 5B ). These localization differences are also apparent in transduced 293CrmA cells at a higher magnification ( Figure 5C and D). These results indicate that the FasL-GFP fusion protein is directed to the cell surface, where it can interact with the Fas receptor in a manner analogous to that of wt FasL.
Regulation of FasL-GFP expression from rAd vector One of our goals was to engineer the ability to regulate the amount of FasL activity produced by our rAd vector in target cells. Therefore, we have performed experiments to establish the levels of FasL expression under induced or uninduced conditions at both the levels of protein synthesis and function. In rAd/FasL-GFP TET vector, expression of FasL-GFP fusion protein is designed to be activated by the binding of the tetR-VP16 fusion protein (constitutively expressed from the same vector; see Figure 2C) to the heptamer of tet-operators upstream of a minimal CMVie promoter. 29 The presence of doxycycline in the cell should inhibit this binding -and therefore the expression of FasL-GFP -in a concentration-dependent manner.
Figure 4 Efficient induction of apoptosis by rAd/FasL-GFP TET vector. HeLa cells were transduced by rAd/FasL-GFP TET (A-C) or rAd/LacZ (E-G), each at an MOI of 0.4 (A, E), 2 (B, F), 10 (C, G), or none (D, H). Twenty-four h after transduction, cells were either stained for apoptosis using the TUNEL kit (A-D) to determine the number of the apoptotic cells or for ␤-galactosidase expression using X-gal stain (E-H) to determine the percentage of transduced cells.
Gene Therapy First, we determined the amounts of FasL-GFP produced in transduced cells by using Western blot analysis. We infected primary rat myoblasts with rAd/FasL-GFP TET at an MOI of 2 and cultured these cells in the absence or presence of doxycycline, a tetracycline derivative. Low MOI was chosen to maximize number of cells transduced with a single copy of the vector. After 48 h, cells were lysed and the lysates analyzed by Western blotting using a polyclonal antibody against the extracellular domain of FasL. A single specific band larger than the predicted size of wt FasL was detected ( Figure  6E ). The intensity of the band decreased with the increasing concentration of doxycycline, and no band could be detected in the cell lysates that had been cultured in the presence of 0.5 mg/l or a higher concentration of doxycycline ( Figure 6C ). No FasL-specific band was observed in cells transduced with a control vector ( Figure 6B ). No bands of lesser size, corresponding to the breakdown or cleavage produces, were detected either in the cell lysates ( Figure 6 ) or in the medium supernatant (data not shown). These results indicate that the amount of FasL-GFP protein produced in the cell from the rAd/FasL-GFP TET vector can be regulated by the concentration of doxycycline in culture medium, and that this protein is stable and does not undergo appreciable cleavage once on the cell surface of rat myoblasts. 
Figure 5 Detection and localization of GFP and FasL-GFP in cells transduced with rAd/FasL-GFP TET and rAd/GFP vectors. Skeletal rat myoblasts (A, B) or 293CrmA cells (C, D) were transduced with rAd/FasL-GFP TET (A, C) or rAd/GFP (B, D) at an MOI of 5. Twenty-four hours after transduction, cells were examined using a fluorescent microscope with FITC filter set. Selected cells are shown. Note cell membrane localization of fluorescence in cells transduced with rAd/FasL-GFP TET (A and C) and even distribution of fluorescence in cells transduced with rAd/GFP (B and D).
cycline. HeLa cells were analyzed 12 h after transduction using the TUNEL assay. The results are shown in Figure  7 . Apoptosis of HeLa cells increased with the decreasing concentration of doxycycline in the media, but without a significant corresponding increase in GFP fluorescence (data not shown). To demonstrate co-regulation of apoptosis with the GFP activity, we examined the rAd/FasL-GFP TET -transduced LNCaP cells with fluorescent microscope 36 h after transduction (Figure 8 ). With the decreasing concentration of doxycycline, the number of cells with apoptotic morphology increased, as did the intensity of GFP fluorescence observed. These results further confirm that the induction of apoptosis in cells transduced with rAd/FasL-GFP TET can be regulated by doxycycline and that apoptosis is induced by the expression of FasL-GFP protein and not by other factors, such as adenovirus vector infection or the expression of tTA protein.
Discussion
Currently, there is considerable interest in the role that FasL-induced apoptosis plays in immune response, autoimmune diseases, tumorigenesis, organ transplantation and gene therapy. In this context, a replication-incompetent adenoviral vector that can deliver a FasL gene to various cell types in vivo is a very useful tool. Such vectors have been developed and tested for their ability to confer immune privilege to target cells 26, 30, 37 or to eliminate these cells (in the case of tumors) through the FasFasL cell death pathway. 27, 38 Paradoxically, rAd vectors used to accomplish these two very different goals are essentially the same, in that they are first or second generation vectors designed to generate high levels of FasL expression either constitutively 30, [37] [38] [39] or after induction. 40 Since it may be advantageous to observe the effects of FasL expression at both high and low levels in a number of tissues and cell types, we set out to develop an Ad5-based vector, which expresses murine FasL-GFP fusion protein under the control of a regulatable TRE promoter. We combined FasL activity with the strong fluorescence of GFP in a fusion gene, so that the resulting protein could be easily distinguished from the endogenous FasL and observed and quantified by virtue of GFP fluorescence. By placing the fusion gene under the control of tetracycline-responsive activator protein and constitutively expressing this activator in the same vector, we were able to regulate FasL activity in vector-transduced cells. Our vector design, which delivers an entire tet-regulated gene expression system, is more efficient and economical than multiple vector strategies, 31 and can be applied to any situation
Figure 6 Regulation of FasL-GFP expression by doxycycline after transduction of 293CrmA cells with rAd/FasL-GFP TET . Primary rat myoblasts were infected with rAd/FasL-GFP TET or control vector at an MOI of 2 in the presence of different concentrations of doxycycline. After 24 h, cells were harvested, lysed, and lysates analyzed by Western blot as described in Materials and methods. Lane A, recombinant FasL C-terminal, 100 ng; lane B, cells infected with rAd/GFP; lanes C-E, cells infected with rAd/FasL-GFP TET at doxycycline concentrations of 0.5 mg/l, 0.1 mg/l (D), or none (E). Positions of molecular mass marker proteins are indicated in kDa on the right side of the blot. Black arrow, position of FasL-GFP fusion protein at an apparent size of 50 kDa; gray arrow, position of the Cterminal FasL fragment at 19 kDa.
where regulation of protein expression is desired, for example, by replacing the CMVie with a tissue-specific promoter.
Although wt FasL is a membrane protein, a significant amount of soluble FasL (sFasL) is produced as the result of metalloproteinase cleavage of the extracytoplasmic Cterminal domain. This sFasL is thought to have activities quite different from -and possibly antagonistic to -the membrane-bound FasL. 11 Generation of sFasL has been most clearly demonstrated with human FasL, 12 ,41 and may not be as extensive with the murine version. We have not been able to detect sFasL in the culture media of any cell lines that we have transduced with rAd/FasL-GFP TET using our polyclonal FasL antibody. Neither did we detect any cleavage or degradation products of the fusion protein in total cell lysates using either anti-FasL or anti-GFP antibodies (not shown). The apparent high stability of the FasL-GFP fusion protein will be of benefit in observing and characterizing its expression and activity. In addition, we are developing rAd vectors that will express either completely soluble or completely noncleavable forms of FasL to help elucidate what roles these different versions play in all aspects of FasL function. We have confirmed that the fusion protein retains full FasL activity as well as strong GFP fluorescence, and is localized to the cellular membrane in cultured cells. Following expression of the fusion protein, GFP fluorescence was observed in the perinuclear space and cytoplasm of the cells, indicating an association with extranuclear organelles, presumably Golgi and rough endoplasmic reticulum ( Figure 5 ).
In the regulated protein expression system utilized in this study, the presence of doxycycline inhibits the binding of tTA to TRE and turns off FasL-GFP transcription Gene Therapy in a dose-dependent manner. For reasons related to promoter interference, we inserted the constitutively expressed activator into the E1 region and the TREdriven FasL-GFP expression cassette into a novel cloning site between the E4 promoter and the right ITR of Ad5. We reasoned that this arrangement would minimize the effect of the E1A enhancer (present within the packaging region of adenovirus) 32, 33 and the CMVie enhancer on the TRE, and thus reduce background expression of the fusion protein in the presence of inhibitor. This system performed successfully in the context of adenoviral vector, such that the expression of FasL-GFP was efficiently regulated by varying the doxycycline concentrations in cell culture medium (Figures 6 and 8) .
In the course of our experiments, we have observed that 293 cells are susceptible to FasL-induced apoptosis. This effect acts to limit significantly the titers of rAd vectors expressing FasL. This is true even if regulated or tissue-specific promoters are used to express FasL protein, since high levels of protein expression are unavoidable in the course of vector replication in 293 cells. In order to overcome this problem, we have generated a 293 cell line which constitutively expresses CrmA. This protein acts specifically to inhibit the activity of regulatory caspases, which are integral to the Fas apoptosis pathway. 7, 36, [42] [43] [44] By producing our FasL-containing vectors in these cells, we have obtained significant improvements in vector titers.
In summary, we have developed and tested a rAd vector that expresses a novel FasL-GFP fusion protein under the control of a tetracycline-regulated gene expression system. This vector combines high titers and efficient transgene delivery to multiple types of dividing and nondividing cells with convenient regulation of protein expression and easy detection of the fusion protein in both living and fixed cells. We believe that this vector will be a valuable tool in the study of Fas-mediated apoptosis in the fields of immunology, transplantation and cancer therapy.
Materials and methods Cells
HeLa, 293 and LNCaP cells were obtained from the American Type Culture Collection (Manassas, VA, USA) (ATCC CCL-2, ATCC CRL-1573 and ATCC CRL-1740, respectively) and maintained as monolayers at 37°C under 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) from Gibco BRL (Rockville, MD, USA) supplemented with 10% cosmic calf serum (CCS) from HyClone (Logan, UT, USA) and 1% penicillin/ streptomycin (Mediatech, Herndon, VA, USA). Cultured rat myoblasts (generously provided by Dr R Lee, Department of Cardiovascular Disease, UCSF) were maintained in H-21 (Mediatech) media supplemented with 20% fetal bovine serum (FBS) from HyClone and 1% each of penicillin/streptomycin and fungizone (Mediatech).
For DNA transfections, 5 × 10 5 cells per well were seeded on six-well plates (Greiner, Frickenhausen, Germany) and transfected 24 h later using Lipofect-AMINE (Gibco BRL) according to the manufacturer's instructions.
To produce a 293 cell line that expresses Cowpox virus (Chordopoxvirinae) cytokine response modifier A (crmA), pCrmA-I-Neo was transfected into 293 cells. Neo-positive clones were selected by adding G418 to the media at 0.4 g/l for 4 weeks, at the end of which time individual clones were picked, propagated and assayed for CrmA expression by their resistance to FasLinduced apoptosis.
Construction of plasmids and recombinant adenoviral vectors
Vectors pEGFP-1 and pEGFP1-C1 were obtained from Clontech (Palo Alto, CA, USA). They contain a redshifted variant of wt GFP gene, with brighter fluorescence and 'humanized' codon usage. 45 This protein is referred to as 'GFP' in this study. Mouse FasL cDNA sequence in a Bluescript (Invitrogen) vector was generously provided by Dr Shigekazu Nagata (Osaka Bioscience Institute). Vectors pUHD10-3 and pUHD15-1 29 were generously provided by Dr H Bujard (Center for Molecular Biology, University of Heidelberg, Germany). Vector pcDNA3(−) was obtained from Invitrogen (Carlsbad, CA, USA). The LacZ gene was cloned into this plasmid to generate pcDNA3.LacZ. FasL-GFP fusion gene was constructed by inserting DNA coding for aa 11 to aa 279 of the murine Fas ligand in-frame downstream of the GFP sequence in pEGFP-C1, to generate pC.GFsl. The fusion gene from pC.GFsl was inserted into pUHD10-3 to produce p10-3.GFsl. Cowpox virus (Chordopoxvirinae) cytokine response modifier A (crmA; CPV-W2) cDNA in pcDNA3 vector was generously provided by Dr Vishva M Dixit (Genentech). The CrmA gene was excised from pcDNA3 and inserted into pIRES-Neo vector (Clontech) to generate pCrmA-I-Neo.
Details of the construction of shuttle vectors for the insertion of transgenes into the E1 region of adenovirus will be described elsewhere, as will the strategy for assembling recombinant Ad (rAd) vectors in vitro. Briefly, GFP, FasL, FasL-GFP and LacZ genes were cloned into the E1 shuttle vector, pLAd-CMV, to generate pLAd-C.Gf, pLAd-C.Fsl, pLAd-C.GFsl and pLAd-C.Lz constructs, respectively (see Results, Figure 2A ). The Tet-OFF fusion activator protein expression cassette was extracted from pUHD15-1 and inserted into pLAd-CMVie to generate pLAd-C.tTa. The FasL-GFP fusion gene expression cassette was excised from p10-3.GFsl and inserted into pRAd.mcs, a shuttle vector for transgene insertion between E4 and right ITR of Ad5. The resulting construct was called pRAd-T.GFsl ( Figure 2B ).
The assembly of rAd/FasL-GFP TET vector is shown in Figure 2C . Other rAd genomes used in this study were constructed using a similar strategy. All vectors were based on Ad5sub360 (⌬E3) with additional deletion of all E4 ORFs with the exception of ORF6. 46 
Propagation of viral vectors
The 293 cells, which provide Ad5 E1a and E1b functions in trans, 47 were transfected with the ligation mixture containing the rAd vector DNA using the LipofectAMINE method. Transfected cells were maintained until adenovirus-related cytopathic effects (CPE) were observed (typically between 7 and 14 days), at which point the cells were collected. Vector propagation and amplification was then achieved by standard techniques. The stocks were titrated on 293 or 293CrmA cells and plaques were scored to determine vector yields as p.f.u./ml. Vectors were also titrated using GFP fluorescence or X-gal staining, as appropriate. In both cases, titer estimates were in good agreement with p.f.u./ml. FasL-GFP fluorescence was observed using an Axiovert 25 inverted microscope with fluorescent lamp attachment (Zeiss Optical Systems, Thornwood, NY, USA) and FITC excitation/emission filter set (Chroma Technology Corp, Brattleboro, VT, USA).
Western blot analysis
Ten cm plates (Greiner) were seeded with 10 6 cells of primary rat myoblasts. After 24 h, plates were infected with rAd/FasL-GFP TET or control vector at an MOI of 2. At 24
Gene Therapy h after infection, the plates were washed twice with PBS. The cells were collected and lysed in 200 l of cell lysis buffer containing 50 mm Tris-HCl (pH 7.8), 1 mm EDTA, 2% SDS, 0.1% Bromophenol Blue, 1 mm PMSF (Sigma, St Louis, MO, USA), 50 g/ml leupeptin (Sigma), 2 g/ml aprotinin (Sigma) and 1 ng/ml pepstatin (Sigma). The samples were boiled for 5 min and 1/10 of the original amount (10 6 cells) was loaded per lane on an 8% SDS-PAGE minigel (BioRad, Melville, NY, USA), which was run at 20 mA for 3 h. Human recombinant FasL (19 kDa C-terminal fragment) was obtained from Santa Cruz Laboratories (Santa Cruz, CA, USA). The proteins were transferred to a nitrocellulose membrane (Amersham Life Science, Piscataway, NJ, USA) using a semi-dry gel transfer apparatus (BioRad). The membrane was blocked by incubation (2 h at 37°C) in a solution containing 10 mm Tris-HCl (pH 7.5), 140 mm NaCl, 3% (w/v) BSA, 5% (w/v) powdered milk, 0.2% (v/v) Tween-20 (Amresco, Solon, OH, USA) and 0.02% (w/v) sodium azide (Sigma). The polyclonal rabbit anti-FasL antibody (Santa Cruz Laboratories) was diluted 1:100 with blocking solution and incubated with the membrane for 2 h at ambient temperature. The blot was washed with 10 mm Tris-HCl (pH 7.5) and 140 mM NaCl solution twice, then incubated with goat anti-rabbit IgG conjugated with HRPO (Caltag, Burlingame, CA, USA) diluted 1:10000. The blot was developed in ECL reagent (Amersham Life Science) overnight and visualized with Kodak X-ray film (Sigma).
Detection of apoptosis
Early detection of apoptosis in cultured adherent cells was accomplished by utilizing the In Situ Cell Death Detection Kit, AP (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's instructions. This kit utilizes the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) process to incorporate fluorescein at free 3Ј-OH DNA ends and detect it with anti-fluorescein antibody conjugated to alkaline phosphatase. After substrate reaction, stained cells can be visualized using light microscopy.
